In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.

Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players. 

Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.

After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.